VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsDavid F. Stojdl, John C. Bell, Laurent Poliquin et al.|Cancer Cell|2003Cited by 850
Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood FlowCaroline J. Breitbach, John C. Bell, Jennifer M Paterson et al.|Molecular Therapy|2007Cited by 277
Targeting Tumor Vasculature With an Oncolytic VirusCaroline J. Breitbach, John C. Bell, Naomi S. De Silva et al.|Molecular Therapy|2011Cited by 202
Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell VaccineChantal G. Lemay, Rebecca C. Auer, Julia L. Rintoul et al.|Molecular Therapy|2012Cited by 93